Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
English (International)
Kymera Therapeutics Inc
Closed
SectorHealthcare
29.85 0.37
Overview
Share price change
24h
Min
28.92
Max
29.99
Income | 5.2M -66M |
|---|---|
Sales | 15M 22M |
EPS | -0.82 |
Profit margin | -296.747 |
Employees | 208 |
EBITDA | -8.3M -69M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +80.54% upside |
Next Earnings | 7 Aug 2025 |
|---|
Market Cap | -92M 2.1B |
|---|---|
Previous open | 29.48 |
Previous close | 29.85 |
News Sentiment
By Acuity
50%
50%
173 / 382 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Kymera Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Kymera Therapeutics Inc Forecast
Price Target
By TipRanks
80.54% upside
12 Months Forecast
Average 53.71 USD 80.54%
High 70 USD
Low 38 USD
Based on 15 Wall Street analysts offering 12 month price targets forKymera Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
173 / 382 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
